A RAIR–ATC transcriptional axis and multimodal drug-response modelling reveal class-level vulnerabilities in thyroid cancer
Siying Wang, Dechun Zhang, Weixuan Liu, Mengqian Zhu, Rongfang Li, Zhenyu Liu, Pei Wu, Tianyu Liu · 2026
Read A RAIR–ATC transcriptional axis and multimodal drug-response modelling reveal class-level vulnerabilities in thyroid cancer by Siying Wang, Dechun Zhang, Weixuan Liu, Mengqian Zhu, Rongfang Li, Zhenyu Liu, Pei Wu, Tianyu Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13223037.txt.
Description
Siying Wang and seven co-authors published a 2026 study linking two hard thyroid cancer states through one gene program, in search of drug weaknesses. Radioiodine-refractory papillary cancer and anaplastic cancer are the deadliest forms of the disease. Merging many gene data cohorts, the team distilled a shared signature of the two states, built on tissue remodeling, blood vessel, and inflammation programs.
The signature graded tumors smoothly and traveled well to cell lines. In a large drug-response database, vessel-growth and RAF-pathway drug classes hit signature-high lines hardest. A combined prediction model beat simpler baselines. One drug, sorafenib, validated the pattern in a lab model, killing cells dose by dose and damping the predicted pathway. The authors offer the signature as a therapy-picking aid.
Catalog record
| CREATOR | Siying Wang, Dechun Zhang, Weixuan Liu, Mengqian Zhu, Rongfang Li, Zhenyu Liu, Pei Wu, Tianyu Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 80 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |